ArticleOncotarget2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Conceptualization of an Ex Vivo Organ Culture (EVOC) Model for Human Seminoma: A Pilot Study.International journal of molecular sciences · 2025Article
- Local recurrences for mixed germ cell tumors without scrotal violation, is metastatic disease around the corner? A case report.Future science OA · 2024Article
- Single-cell landscape identified SERPINB9 as a key player contributing to stemness and metastasis in non-seminomas.Cell death & disease · 2024Article
- Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.Journal of clinical medicine · 2024Article
- Intratumoral Heterogeneity, Chemoresistance and Lymph Node Landing Zone Prognosis in Testicular Tumors Based on Histopathological Characteristics.Annals of surgical oncology · 2024Article
- Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages.Medicina (Kaunas, Lithuania) · 2023Article
- Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care.Cancers · 2022Article
- Article
- Article
- Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors.Cancers · 2021Review
- Curing Cancer: Lessons from a Prototype.Cancers · 2021Article
- Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers.Journal of cell science & therapy · 2021Article
- Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.Cancers · 2020Article
- Paraneoplastic Limbic Encephalitis in a Patient with Primary Well-differentiated Teratoma and Metastatic Poorly Differentiated Embryonal Carcinoma.The Yale journal of biology and medicine · 2020Article
- Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.Translational andrology and urology · 2020Review
- Human germ cell tumours from a developmental perspective.Nature reviews. Cancer · 2019Review
- Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development.British journal of cancer · 2019Article
- Evaluating Tumor Evolution via Genomic Profiling of Individual Tumor Spheroids in a Malignant Ascites.Scientific reports · 2018Article
- The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.International journal of molecular sciences · 2017Review
- Recent developments in the management of germ cell tumors.Current opinion in oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNonseminomatous germ cell tumor of the testis (NSGCT) is largely curable. However, a small group of patients develop refractory disease. We investigated the hypothesis that intratumoral heterogeneity contributes to the emergence of chemoresistance and the development of refractory tumor subtypes.
resultsOur institution's records for January 2000 through December 2010 included 275 patients whose primary tumor showed pure embryonal carcinoma (pure E); mixed embryonal carcinoma, yolk sac tumor, and teratoma (EYT); or mixed embryonal carcinoma, yolk sac tumor, seminoma, and teratoma (EYST). Patients with EYST had the highest cancer-specific mortality rate (P = .001). They tended to undergo somatic transformation (P = .0007). Two of 5 patients with clinical stage I EYST who had developed recurrence during active surveillance died of their disease. MATERIALS AND
methodsIn this retrospective study, we evaluated consecutive patients who had been diagnosed with the three most common histological phenotypes of NSGCT. Chemoresistance was defined as the presence of teratoma, viable germ cell tumor, or somatic transformation in the residual tumor or the development of progressive or relapsed disease after chemotherapy. In a separate prospective study, we performed next-generation sequencing on tumor samples from 39 patients to identify any actionable genetic mutations.
conclusionsOur data suggest that patients with EYST in their primary tumor may harbor a potentially refractory NSGCT phenotype and are at increased risk of dying from disease. Despite intratumoral heterogeneity, improved patient selection and personalized care of distinct tumor subtypes may optimize the clinical outcome of patients with NSGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.